Literature DB >> 32633395

METTL14 regulates M6A methylation-modified primary miR-19a to promote cardiovascular endothelial cell proliferation and invasion.

B-Y Zhang1, L Han, Y-F Tang, G-X Zhang, X-L Fan, J-J Zhang, Q Xue, Z-Y Xu.   

Abstract

OBJECTIVE: Increasing evidence indicated that N6-methyl-adenosine (M6A) played a key role in a variety of pathophysiological processes. Methylases could promote the processing of mature mi-RNA in a M6A-dependent manner, thereby participating in the pathological cells' occurrence and development. However, the regulatory mechanism of M6A in atherosclerosis (AS) was still unclear. PATIENTS AND METHODS: Quantificational Real-time polymerase chain reaction (qRT-PCR) was used to detect the relative expression levels of M6A, methyltransferase, demethylase transferase, miR-19a and other mi-RNA in atherosclerotic vascular endothelial cells (ASVEC). Cell Counting Kit (CCK8) was used to detect cell proliferation, the expression of PCNA was measured by Western Blot (WB) and qRT-PCR. Transwell assays were used to detect the invasion ability of ASVEC. Co-immunoprecipitation (Co-IP) was used to detect the binding of METTL14 to DGCR8. RNA Immunoprecipitation (RIP) was used to detect the binding of METTL14 to miR-19a.
RESULTS: M6A modification levels and METTL14 methylation transferase were significantly overexpressed in ASVEC. Silencing METTL14 inhibited the proliferation and invasion of ASVEC. Low expression of METTL14 suppressed the binding of methylated RNA and RNA splicing related protein DGCR8. Moreover, silencing METTL14 significantly inhibited the expression of miR-19a while promoted the expression of primary pre-miR-19a. However, high expression of METTL14 obviously increased the expression of DGCR8 and methylated m6A. Furthermore, silencing miR-19a inhibited the proliferation and invasion of ASVEC.
CONCLUSIONS: METTL14 increased the M6A modification of pri-miR-19a and promoted the processing of mature miR-19a, thus promoting the proliferation and invasion of ASVEC. These results suggested that METTL14/ M6A/ miR-19a signaling pathway may be a new target for atherosclerosis treatment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32633395     DOI: 10.26355/eurrev_202006_21694

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  19 in total

1.  METTL3 mediates Ang-II-induced cardiac hypertrophy through accelerating pri-miR-221/222 maturation in an m6A-dependent manner.

Authors:  Rui Zhang; Yangyang Qu; Zhenjun Ji; Chunshu Hao; Yamin Su; Yuyu Yao; Wenjie Zuo; Xi Chen; Mingming Yang; Genshan Ma
Journal:  Cell Mol Biol Lett       Date:  2022-07-14       Impact factor: 8.702

Review 2.  m6A Methylation in Cardiovascular Diseases: From Mechanisms to Therapeutic Potential.

Authors:  Longbo Li; Nannan Xu; Jia Liu; Zhenzhen Chen; Xu Liu; Junnan Wang
Journal:  Front Genet       Date:  2022-06-28       Impact factor: 4.772

3.  ALKBH5 inhibits TNF-α-induced apoptosis of HUVECs through Bcl-2 pathway.

Authors:  Xiaoshan Zhang; ShiBing Deng; Yang Peng; Han Wei; Zhiming Tian
Journal:  Open Med (Wars)       Date:  2022-06-15

Review 4.  Regulation and roles of RNA modifications in aging-related diseases.

Authors:  Zeyidan Jiapaer; Dingwen Su; Lingyang Hua; Helge Immo Lehmann; Priyanka Gokulnath; Gururaja Vulugundam; Shannan Song; Lingying Zhang; Ye Gong; Guoping Li
Journal:  Aging Cell       Date:  2022-06-19       Impact factor: 11.005

5.  HIF-1α Regulated WTAP Overexpression Promoting the Warburg Effect of Ovarian Cancer by m6A-Dependent Manner.

Authors:  Yuanyuan Lyu; Yilin Zhang; Yuhan Wang; Yonghong Luo; Huafeng Ding; Peiling Li; Guantai Ni
Journal:  J Immunol Res       Date:  2022-06-12       Impact factor: 4.493

Review 6.  N6-Adenosine Methylation (m6A) RNA Modification: an Emerging Role in Cardiovascular Diseases.

Authors:  Ye-Shi Chen; Xin-Ping Ouyang; Xiao-Hua Yu; Petr Novák; Le Zhou; Ping-Ping He; Kai Yin
Journal:  J Cardiovasc Transl Res       Date:  2021-02-25       Impact factor: 4.132

7.  METTL14-Mediated miR-30c-1-3p Maturation Represses the Progression of Lung Cancer via Regulation of MARCKSL1 Expression.

Authors:  Fei Li; Jing Zhao; Lei Wang; Yantong Chi; Xiaori Huang; Wei Liu
Journal:  Mol Biotechnol       Date:  2021-09-29       Impact factor: 2.695

8.  Methyltransferase-like 14 silencing relieves the development of atherosclerosis via m6A modification of p65 mRNA.

Authors:  Yingjie Liu; Gang Luo; Quan Tang; Yang Song; Daxing Liu; Hongjuan Wang; Junliang Ma
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

9.  The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.

Authors:  Xiaotian Shen; Beiyuan Hu; Jing Xu; Wei Qin; Yan Fu; Shun Wang; Qiongzhu Dong; Lunxiu Qin
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

10.  METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA.

Authors:  Liping Meng; Hui Lin; Xingxiao Huang; Jingfan Weng; Fang Peng; Shengjie Wu
Journal:  Cell Death Dis       Date:  2022-01-10       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.